Skip to main content
Critical Care logoLink to Critical Care
. 2014 Dec 12;18(6):704. doi: 10.1186/s13054-014-0704-9

Serum miR-122 correlates with short-term mortality in sepsis patients

Huijuan Wang 1,2,#, Bingxiang Yu 3,#, Jie Deng 4, Yang Jin 5,, Lixin Xie 1,
PMCID: PMC4262971  PMID: 25672224

Sepsis is one of the leading causes of death in the ICU. The pathogenesis of sepsis remains incompletely understood, thereby impeding the development of therapeutics, diagnostics and biomarkers to predict outcomes [1]. Our previous studies have proved that miR-122, miR-193b*, miR-483-5p and miR-574-5p were all differentially expressed between sepsis survivors and non-survivors, differentiated by 28-day mortality [2,3]. However, whether these biomarkers related to patients with both sepsis and acute respiratory distress syndrome (ARDS) remains unclear. Here we evaluate the levels of these four microRNAs (miRNAs) along with C-reactive protein (CRP), procalcitonin (PCT), Sequential Organ Failure Assessment (SOFA) score, and Acute Physiology and Chronic Health Evaluation (APACHE) II score to determine the ideal biomarkers for sepsis patients.

Serum samples were collected from 232 sepsis patients who were admitted to ICUs of the Chinese PLA General Hospital. All the patients met the definition of sepsis developed in 2003 [4]. Inclusion and exclusion criteria are described in Table 1. Another 24 normal individuals were also included in this study. Serum levels of miRNAs, CRP and PCT were analyzed using methods as described in detail previously [3]. This study was approved by the ethics committee of the Chinese PLA General Hospital. Appropriate informed consent was obtained from each patient and normal individual.

Table 1.

Inclusion and exclusion criteria

Inclusion criteria Exclusion criteria
1) Sepsis patients all met the definitions of the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference [4] 1) Patients who were younger than 18 years old
2) Patients who were immunosuppressed
3) Patients who did not receive adequate treatment
4) Patients who did not give their written informed consent
2) All patients received standard protocols of clinical care

The clinical data of these 232 patients are shown in Table 2. After comparison of the levels of the four miRNAs in three pairs of groups (normal individuals and sepsis patients, survivors and non-survivors, sepsis without ARDS and sepsis plus ARDS), only the cycle threshold of mir-122 was differentially expressed in all three (P < 0.01) (Figure 1). Univariable and multivariable regression analyses were then used to evaluate the association between miR-122 and 28-day mortality in different ICUs. After adjustment using clinical data and additional parameters (SOFA score, APACHE II score and ARDS), the odds ratio of miR-122 association with 28-day mortality was around 0.376 to 0.868 (P < 0.05) in the different ICUs. The area under the curve for the predictive value of miR-122 was around 0.706 to 0.770 (P < 0.01) with high sensitivity and specificity (Table 3). As a result, only miR-122 can be used as a biomarker with regards to patients with both sepsis and ARDS. miR-122 is a liver-specific miRNA and levels of it in serum were correlated with drug-induced liver injury [5]. We reported that miR-122 correlated with coagulation disorders in sepsis patients and serum levels of miR-122 correlated with serum antithrombin III levels [6]. Our study reveals a potential novel target to develop a biomarker for sepsis prognosis and therapeutic strategies.

Table 2.

Clinical characteristics of the 232 sepsis patients

Category Variables Sepsis (n = 232)
Demographic parameters Gender (male/female) 169/63
Age in years (median (range)) 59 (19, 91)
Clinical parameters ICU type
  Medical 232 (100%)
  Cardiac 79 (34.05%)
  Surgical 95 (40.95%)
  Trauma 25 (10.77%)
  Cancer 24 (10.34%)
  Other 15 (6.46%)
APACHE II score 18 (1, 39)
SOFA score 7 (0, 19)
Acute kidney injury 61 (26.29%)
Mechanical ventilation 171 (73.71%)
Heat failure 121 (52.15%)
Liver failure 103 (44.39%)
ARDS 60 (28.17%)a
28-day mortality 45.69%
Biomarkers miR-122 17.75 ± 3.40 cycles
miR-193b* 17.73 ± 4.81 cycles
miR-574-5p 21.19 ± 3.64 cycles
miR-483-5p 18.99 ± 4.24 cycles
CRP (mg/dl) 8.9 (0.1, 35)
PCT (ng/ml) 4.63 (0.05,119.44)

aARDS data of 19 patients were missing. APACHE, Acute Physiology and Chronic Health Evaluation; ARDS, acute respiratory distress syndrome; CRP, C-reactive protein; PCT, procalcitonin; SOFA, Sequential Organ Failure Assessment. APACHE II score, SOFA score, CRP and PCT are all given as median (range).

*ARDS data of 19 patients were missing.

Figure 1.

Figure 1

Cycle thresholds of the four microRNAs (miRNAs) in the three pairs of groups. ARDS, acute respiratory distress syndrome.

Table 3.

The association between miR-122 levels and 28-day mortality in sepsis patients

All patients (n = 232) RICU (n = 67) SICU (n = 121) EICU (n = 44)
Odds ratios of miR-122 (95% CI)
Unadjusteda 0.775 (0.703, 0.853) 0.776 (0.664, 0.908) 0.77 (0.662, 0.894) 0.764 (0.610, 0.956)
P < 0.001 P = 0.001 P = 0.001 P = 0.019
Adjustedb 0.789 (0.713, 0.872) 0.777 (0.663, 0.911) 0.763 (0.655, 0.888) 0.650 (0.474, 0.891)
P < 0.001 P = 0.002 P < 0.001 P = 0.007
Adjustedb + 0.772 (0.690, 0.863) 0.781(0.665, 0.918) 0.791(0.677,0.925) 0.631 (0.448, 0.890)
SOFA score P < 0.001 P = 0.003 P = 0.003 P = 0.009
Adjustedb + 0.815 (0.734, 0.905) 0.709 (0.578, 0.870) 0.753 (0.639, 0.887) 0.622 (0.431, 0.897)
APACHE II score P < 0.001 P = 0.001 P = 0.001 P = 0.011
Adjustedb + 0.812 (0.724, 0.911) 0.868 (0.647, 0.967) 0.721 (0.599, 0.867) 0.376 (0.133, 0.865)
ARDS P < 0.001 P = 0.023 P = 0.001 P = 0.034
The predictive value of miR-122
AUC (95% CI) 0.732 (0.665, 0.799) 0.763 (0.65,0.877) 0.706 (0.611,0.802) 0.770 (0.574, 0.966)
P-value < 0.001 < 0.001 < 0.001 0.009
Sensitivity 79.5% 75.9% 79.4% 80%
Specificity 63.5% 70.3% 60.7% 81.8%

aUnadjusted by any value. bAdjusted by age and gender. APACHE, Acute Physiology and Chronic Health Evaluation; ARDS, acute respiratory distress syndrome; AUC, are under the curve; EICU, Emergency Intensive Care Unit; RICU, Respiratory Intensive Care Unit; SICU, Surgery’s Intensive Care Unit; SOFA, Sequential Organ Failure Assessment.

Acknowledgements

This work is supported by the general program of the National Natural Science Foundation of China (81170008), and the general program of China’s 12th Five Year Plan and its military (CWS11J094).

Abbreviations

APACHE

Acute Physiology and Chronic Health Evaluation

ARDS

Acute respiratory distress syndrome

CRP

C-reactive protein

miRNA

microRNA

PCT

Procalcitonin

SOFA

Sequential Organ Failure Assessment

Footnotes

Huijuan Wang and Bingxiang Yu are equal contributors.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

HW and BY had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis and performed the experiments. They designed the study, analyzed data and wrote the manuscript. LX and YJ designed the studies, analyzed data and edited the manuscript. JD had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Contributor Information

Huijuan Wang, Email: m13466791738@163.com.

Bingxiang Yu, Email: bingxiang_yu@hotmail.com.

Jie Deng, Email: dengjie.1225@qq.com.

Yang Jin, Email: yjin@rics.bwh.harvard.edu.

Lixin Xie, Email: xielx@263.net.

References

  • 1.Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K, German Competence Network Sepsis (SepNet) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125–139. doi: 10.1056/NEJMoa070716. [DOI] [PubMed] [Google Scholar]
  • 2.Wang H, Zhang P, Chen W, Feng D, Jia Y, Xie L. Serum microRNA signatures identified by Solexa sequencing predict sepsis patients’ mortality: a prospective observational study. PLoS One. 2012;7:e38885. doi: 10.1371/journal.pone.0038885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Wang H, Meng K, Chen W, Feng D, Jia Y, Xie L. Serum miR-574-5p: a prognostic predictor of sepsis patients. Shock. 2012;37:263–267. doi: 10.1097/SHK.0b013e318241baf8. [DOI] [PubMed] [Google Scholar]
  • 4.Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2001;2003:1250–1256. doi: 10.1097/01.CCM.0000050454.01978.3B. [DOI] [PubMed] [Google Scholar]
  • 5.Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, French NS, Dhaun N, Webb DJ, Costello EM, Neoptolemos JP, Moggs J, Goldring CE, Park BK. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology. 2011;54:1767–1776. doi: 10.1002/hep.24538. [DOI] [PubMed] [Google Scholar]
  • 6.Wang HJ, Deng J, Wang JY, Zhang PJ, Xin Z, Xiao K, Feng D, Jia YH, Liu YN, Xie LX. Serum miR-122 levels are related to coagulation disorders in sepsis patients. Clin Chem Lab Med. 2014;52:927–933. doi: 10.1515/cclm-2013-0899. [DOI] [PubMed] [Google Scholar]

Articles from Critical Care are provided here courtesy of BMC

RESOURCES